The UAB Comprehensive Cancer Center is currently in its 39th year of continuous NCI CCSG funding. The Cancer Center has a well-established track record of translational research with a nnajor emphasis on investigator-initiated early phase 1 and II trials, many of which emanate from Cancer Center scientific discoveries. In addition, the Center has major strengths in the area of cancer health disparity research. Current funding levels are $106.1M total direct, $32.0M NCI, $48.2M other NIH, $8.7M peer-reviewed, and $17.1M non-peer reviewed. There are 244 members representing 10 schools and 33 departments. The Cancer Center's research enterprise is organized around seven programs, including three basic science programs - Tumor Immunology, Cancer Cell Biology, and Virology;two translational/dinical programs - Experimental Therapeutics and Neuro-Oncology;and two prevention and control programs - Cancer Chemoprevention and Cancer Control and Population Sciences. The Center's research enterprise is supported by 15 shared facilities that support and enhance our basic, clinical, translational, and prevention and control research by providing research technology, advanced genomics, biostatistics/bioinformatics, tissue procurement, human and animal imaging, and recruitment and retention of trial participants. Under current leadership, we have successfully recruited six new key leaders critical for a successful cancer research program and have recruited another 44 new cancer-focused faculty to various departments in the institution. Institutional support during this funding cycle has included $55M for recruitment and program building, $50M for renovation of cancer facilities including the Wallace Tumor Institute, the center of our cancer enterprise, and another $8.1 M from IMPACT funds to support recruitments. The Cancer Center has enhanced its translational research capabilities via a drug discovery and development initiative within the Experimental Therapeutics Program that incorporates the strength and resources of Southem Research into the Cancer Center via the Alabama Drug Discovery Alliance. In addition, the Cancer Center has forged a relationship with HudsonAlpha Institute for Biotechnology which provides the latest generation of high throughput genomic sequencing and collaborative expertise that will allow multiple programs to further understand the genetic footprints that impact therapeutic response, modify risk and thereby form the basis of individualized care.
NCl-designated Comprehensive Cancer Centers are the centerpiece of the nation's effort to reduce cancer morbidity and mortality. The UAB Comprehensive Cancer Center serves as a major source for more effective approaches to prevention, diagnosis, treatment, and survivorship and as a source for delivery of these discoveries, public and professional education, and ultimately as a resource for the local, regional, and national community.
|Zhang, Wei; Zhai, Ling; Wang, Yimin et al. (2016) Discovery of a novel inhibitor of kinesin-like protein KIFC1. Biochem J 473:1027-35|
|Nebane, N Miranda; Coric, Tatjana; McKellip, Sara et al. (2016) Acoustic Droplet Ejection Technology and Its Application in High-Throughput RNA Interference Screening. J Lab Autom 21:198-203|
|Badiga, Suguna; Chambers, Michelle M; Huh, Warner et al. (2016) Expression of p16(INK4A) in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines. Cancer 122:3615-3623|
|Carvajal, Felipe; Vallejos, Maricarmen; Walters, Beth et al. (2016) Structural domains within the HIV-1 mRNA and the ribosomal protein S25 influence cap-independent translation initiation. FEBS J 283:2508-27|
|Hull, Travis D; Boddu, Ravindra; Guo, Lingling et al. (2016) Heme oxygenase-1 regulates mitochondrial quality control in the heart. JCI Insight 1:e85817|
|Zhang, Wei; Zhai, Ling; Lu, Wenyan et al. (2016) Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening. Chem Biol Drug Des 88:178-87|
|Smith, M Ryan; Vayalil, Praveen K; Zhou, Fen et al. (2016) Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels. Redox Biol 8:136-48|
|Hegde, Shylaja; Kesterson, Robert A; Srivastava, Om P (2016) CRYÎ²A3/A1-Crystallin Knockout Develops Nuclear Cataract and Causes Impaired Lysosomal Cargo Clearance and Calpain Activation. PLoS One 11:e0149027|
|Styles, Nathan A; Shonsey, Erin M; Falany, Josie L et al. (2016) Carboxy-terminal mutations of bile acid CoA:N-acyltransferase alter activity and substrate specificity. J Lipid Res 57:1133-43|
|McNally, Lacey R; Mezera, Megan; Morgan, Desiree E et al. (2016) Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology. Clin Cancer Res 22:3432-9|
Showing the most recent 10 out of 566 publications